Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Victor Perlroth
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 141
- Beta
- 2.18
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 6.24
Financials
Net Income
$-65.64MEBITDA
$-66.78MFree Cash Flow
$-46.59MEPS (diluted)
$-1.05Shares Outstanding (diluted)
62.63M+741.3%Operating Expenses
$66.84MCash & Debt
$125.90MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-229.97M | $-4.32 |
| 2024 | $0.00 | $-176.21M | $-3.35 |
| 2023 | $0.00 | $-260.49M | $-4.97 |
| 2022 | $0.00 | $-333.82M | $-6.39 |
| 2021 | $0.00 | $-266.99M | $-5.16 |
| 2020 | $0.00 | $-133.10M | $-2.91 |
| 2019 | $0.00 | $-47.37M | $-1.23 |
| 2018 | $0.00 | $-41.44M | $-1.16 |
| 2017 | $0.00 | $-27.94M | $-1.05 |
| 2016 | $0.00 | $-17.13M | $-2.30 |
Valuation
KODhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
45-10.00%Social Signal Score
Mentions (11)
- News247wallst.com·6d ago·Neutral
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak? Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.
View source ↗ - 4chan /biz/biz·6d ago·Neutral
>>62736771 KOD? where is KOD anon...he was right
View source ↗ - Newszacks.com·6d ago·Positive
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.
View source ↗ - Newsfool.com·7d ago·Neutral
Why Kodiak Sciences Skyrocketed Today Zenkuda and KSI-501 achieved their primary goals in a Phase 3 study. The global market for retinal drugs could exceed $32 billion by the end of the decade.
View source ↗ - 4chan /biz/biz·7d ago·Neutral
>>62733697 If you had bought KOD at open today you could have made 45% in 45 minutes
View source ↗ - Newsseekingalpha.com·7d ago·Positive
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
View source ↗ - Newsbenzinga.com·8d ago·Negative
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine Kodiak Sciences Inc. (NASDAQ:KOD) on Monday released data from the Phase 3 DAYBREAK trial for patients suffering from wet age-related macular degeneration (wAMD).
View source ↗ - Newsbarrons.com·8d ago·Negative
Kodiak Sciences Stock Pops 64% After Eye-Disease Drugs Pass Key Trial Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.
View source ↗ - Newsprnewswire.com·10d ago·Neutral
…ation Kodiak Sciences to Host Webcast on Monday, September 28 at 8:30 AM Eastern Time PALO ALTO, Calif., Sept. 25, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the company will report topline results from DAYBREAK, a Phase 3 study evaluating both Zenkuda TM (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) for the t…
View source ↗ - Newszacks.com·52d ago·Neutral
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.
View source ↗ - Newszacks.com·55d ago·Neutral
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema Kodiak launches a global phase III study of KSI-501 in DME, testing its dual IL-6 and VEGF approach for durable disease control.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-1.00 per share
Typical surprise -2.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-1.05 vs $-0.96miss
- Thu, May 7$-0.94 vs $-0.93miss
- Tue, Mar 31$-1.04 vs $-1.02miss
- Thu, Nov 13$-1.16 vs $-1.07miss
- Wed, Aug 13$-1.03 vs $-1.01miss
- Wed, May 14$-1.09 vs $-0.89miss
Estimates and results for KOD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KOD officers and directors.
- Bought
- $157.0m
- Sold
- $1.0m
82 trades
2 trades
- Baker Bros. Advisors Lpbought
- Baker Bros. Advisors Lpbought
- Baker Bros. Advisors Lpbought
- Baker Bros. Advisors Lpbought
- Baker Bros. Advisors Lpbought
- Baker Bros. Advisors Lpbought
- Baker Bros. Advisors Lpbought
- Baker Bros. Advisors Lpbought
16 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Dec 12, 2022 (34d later)Sell$1,001 - $15,000
- Chris Jacobshouse · NY27 · disclosed Sep 9, 2022 (53d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.